A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
Open Access
- 4 March 2013
- journal article
- Published by Wiley in International Journal of Cancer
- Vol. 133 (4), 929-936
- https://doi.org/10.1002/ijc.28082
Abstract
The 70‐gene signature (MammaPrint™) has been developed on retrospective series of breast cancer patients to predict the risk of breast cancer distant metastases. The microarRAy‐prognoSTics‐in‐breast‐cancER (RASTER) study was the first study designed to prospectively evaluate the performance of the 70‐gene signature, which result was available for 427 patients (cT1–3N0M0). Adjuvant systemic treatment decisions were based on the Dutch CBO 2004 guidelines, the 70‐gene signature and doctors' and patients' preferences. Five‐year distant‐recurrence‐free‐interval (DRFI) probabilities were compared between subgroups based on the 70‐gene signature and Adjuvant! Online (AOL) (10‐year survival probability n = 219) and high‐risk (n = 208) patients were 97.0% and 91.7%. The 5‐year DRFI probabilities for AOL low‐risk (n = 132) and high‐risk (n = 295) patients were 96.7% and 93.4%. For 70‐gene signature low‐risk–AOL high‐risk patients (n = 124), of whom 76% (n = 94) had not received ACT, 5‐year DRFI was 98.4%. In the AOL high‐risk group, 32% (94/295) less patients would be eligible to receive ACT if the 70‐gene signature was used. In this prospective community‐based observational study, the 5‐year DRFI probabilities confirmed the additional prognostic value of the 70‐gene signature to clinicopathological risk estimations such as AOL. Omission of adjuvant chemotherapy as judged appropriate by doctors and patients and instigated by a low‐risk 70‐gene signature result, appeared not to compromise outcome.This publication has 19 references indexed in Scilit:
- Impact of mammographic screening on the detection of good and poor prognosis breast cancersBreast Cancer Research and Treatment, 2011
- Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?Nature Reviews Clinical Oncology, 2011
- The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of ageAnnals of Oncology, 2010
- Commercialized Multigene Predictors of Clinical Outcome for Breast CancerThe Oncologist, 2008
- Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)The Lancet Oncology, 2007
- Converting a breast cancer microarray signature into a high-throughput diagnostic testBMC Genomics, 2006
- Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trialNature Clinical Practice Oncology, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast CancerJournal of Clinical Oncology, 2005
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerThe New England Journal of Medicine, 2002